Google
OKYO — OKYO PHARMA LTD ADR (Healthcare >> Biotechnology)
OKYO FAQ
What is OKYO's P/E ratio?
OKYO PHARMA LTD ADR (OKYO) currently trades at a P/E ratio of 64,619.98.
What is OKYO's ROE?
OKYO PHARMA LTD ADR reports a Return on Equity (ROE) of 194.44%.
What is OKYO's dividend yield?
OKYO PHARMA LTD ADR offers a dividend yield of 0.00%.
What is OKYO's Deepscope Quality Score?
Deepscope rates OKYO's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OKYO?
Deepscope's AI Timing Score for OKYO is 1 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OKYO belong to?
OKYO PHARMA LTD ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.62
Price
-0.06
(-3.57%)
Day Change
|
|
|---|
OKYO, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.62 |
| PBV / Sector |
-25.35 / 4.63
|
| Earning Per Share | -0.12 |
| PE / Sector |
64,619.98 / 17.43
|
| PEG or PE/Growth / Sector |
-10,971.13 / 0.53
|
| Average 1M Daily Value |
0.07 M
GREAT
|
| Average 1W Daily Value |
0.08 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:05 |
| Symbol | OKYO |
| Name | OKYO PHARMA LTD ADR |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 52.48 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 86.59 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 14/15 Conduit St, London, United Kingdom, W1S 2XJ
Phone: 44 20 7495 2379
Website: https://okyopharma.com
Sector: Healthcare >> Biotechnology
Description: OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
